Allosteric Tuning of Caspase-7: A Fragment-Based Drug Discovery Approach
Journal Article
·
· Angewandte Chemie (International Edition)
- Division of Medicinal and Natural Products Chemistry, College of Pharmacy, University of Iowa, 115 S Grand Ave Iowa City IA 52242 USA
- Department of Biochemistry, College of Medicine, University of Iowa, 51 Newton Road Iowa City IA 52242 USA; Protein Crystallography Facility, Roy J. and Lucille A. Carver College of Medicine, University of Iowa, 51 Newton Road Iowa City IA 52242 USA
- Division of Medicinal and Natural Products Chemistry, College of Pharmacy, University of Iowa, 115 S Grand Ave Iowa City IA 52242 USA; Department of Biochemistry, College of Medicine, University of Iowa, 51 Newton Road Iowa City IA 52242 USA
Not provided.
- Research Organization:
- Lawrence Berkeley National Laboratory (LBNL), Berkeley, CA (United States)
- Sponsoring Organization:
- USDOE Office of Science (SC)
- Grant/Contract Number:
- AC02-05CH11231
- OSTI ID:
- 1623486
- Journal Information:
- Angewandte Chemie (International Edition), Vol. 56, Issue 46; ISSN 1433-7851
- Publisher:
- WileyCopyright Statement
- Country of Publication:
- United States
- Language:
- English
Cited by: 8 works
Citation information provided by
Web of Science
Web of Science
Identification of FDA-approved drugs as novel allosteric inhibitors of human executioner caspases
|
journal | October 2018 |
Proteases: Pivot Points in Functional Proteomics
|
book | October 2018 |
Determination of the binding mechanism of histone deacetylase inhibitors
|
journal | December 2018 |
Similar Records
Discovery of potent, reversible MetAP2 inhibitors via fragment based drug discovery and structure based drug design—Part 2
Discovery of Clinical Candidate 1-{[(2 S ,3 S ,4 S )-3-Ethyl-4-fluoro-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6-carboxamide (PF-06650833), a Potent, Selective Inhibitor of Interleukin-1 Receptor Associated Kinase 4 (IRAK4), by Fragment-Based Drug Design
Fragment- and structure-based drug discovery for developing therapeutic agents targeting the DNA Damage Response
Journal Article
·
Wed Jun 01 00:00:00 EDT 2016
· Bioorganic and Medicinal Chemistry Letters
·
OSTI ID:1623486
+9 more
Discovery of Clinical Candidate 1-{[(2 S ,3 S ,4 S )-3-Ethyl-4-fluoro-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6-carboxamide (PF-06650833), a Potent, Selective Inhibitor of Interleukin-1 Receptor Associated Kinase 4 (IRAK4), by Fragment-Based Drug Design
Journal Article
·
Mon Mar 27 00:00:00 EDT 2017
· Journal of Medicinal Chemistry
·
OSTI ID:1623486
+46 more
Fragment- and structure-based drug discovery for developing therapeutic agents targeting the DNA Damage Response
Journal Article
·
Thu Oct 01 00:00:00 EDT 2020
· Progress in Biophysics and Molecular Biology
·
OSTI ID:1623486
+7 more